Literature DB >> 30183087

Genome-wide DNA methylation profiling of primary colorectal laterally spreading tumors identifies disease-specific epimutations on common pathways.

Liangliang Zhu1, Feihu Yan1,2, Zhen Wang1, Haiyan Dong3, Chengling Bian4, Ting Wang5,6, Enda Yu1, Jing Li3.   

Abstract

Colorectal laterally spreading tumors (LSTs) grow to extremely large size while rarely invade deeply. Also, there is a low tendency to become cancerous. We used the Illumina Human Methylation 450K array to query the main epigenetic difference of LSTs. We built a discovery cohort with 10 matched cases, and a validation cohort with 9 additional matched cases. Our results suggest that LST displays significant decrease in DNA methylation, highlighted by the discovery of 1,018 hypomethylated intergenic regions (IGRs). Comparing to classic differentially methylated probes and regions that overlap transcription starting site and CpG island, IGR-regions were associated more closely with genes involved in functional biological processes and correlated with specific histone modifications. Hypomethylated IGR regions were often annotated as tissue-specific regulatory elements for noncolon tissues and were typically epigenetically silenced in normal colon mucosa. By integration of public data, we defined the commonality and specific epigenetic signatures for adenomas, LSTs and colon adenocarcinomas. Only 435 hypermethylated differentially methylated probes (DMPs) and differentially methylated regions (DMRs) and 517 hypomethylated DMPs and DMRs were shared by the three diseases. However, our pathway-level analysis discovered that genes in four pathways were common target of epimutations in LSTs, adenomas and CRCs. More interestingly, different diseases seem to employ distinct epigenetic insult to disturb specific pathways. Between LST and adenoma, we found eight pathways including Ras signaling and Rap1 signaling pathway were commonly targeted but the epimutation patterns were opposite. Comparison between precancerous conditions and invasive states revealed the key pathways governing the progression to malignancy, including PI3K-Akt pathways.
© 2018 UICC.

Entities:  

Keywords:  DNA methylation; DNA methylation array; epimutation; laterally spreading tumors

Mesh:

Year:  2018        PMID: 30183087      PMCID: PMC6495531          DOI: 10.1002/ijc.31765

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Genome-wide methylation profiling of early colorectal cancer using an Illumina Infinium Methylation EPIC BeadChip.

Authors:  Yu-Ling Wu; Tao Jiang; Wei Huang; Xing-Yu Wu; Peng-Jun Zhang; Ya-Ping Tian
Journal:  World J Gastrointest Oncol       Date:  2022-04-15

2.  A panel of DNA methylation signature from peripheral blood may predict colorectal cancer susceptibility.

Authors:  Justina Ucheojor Onwuka; Dapeng Li; Yupeng Liu; Hao Huang; Jing Xu; Ying Liu; Yuanyuan Zhang; Yashuang Zhao
Journal:  BMC Cancer       Date:  2020-07-25       Impact factor: 4.430

3.  Reduced m6A modification predicts malignant phenotypes and augmented Wnt/PI3K-Akt signaling in gastric cancer.

Authors:  Cheng Zhang; Mengqi Zhang; Sai Ge; Wenwen Huang; Xiaoting Lin; Jing Gao; Jifang Gong; Lin Shen
Journal:  Cancer Med       Date:  2019-06-26       Impact factor: 4.452

4.  Genome-wide analysis of the hypoxia-related DNA methylation-driven genes in lung adenocarcinoma progression.

Authors:  Hongxia Li; Li Tong; Hong Tao; Zhe Liu
Journal:  Biosci Rep       Date:  2020-02-28       Impact factor: 3.840

5.  Birthweight DNA methylation signatures in infant saliva.

Authors:  Chiara Moccia; Maja Popovic; Elena Isaevska; Valentina Fiano; Morena Trevisan; Franca Rusconi; Silvia Polidoro; Lorenzo Richiardi
Journal:  Clin Epigenetics       Date:  2021-03-19       Impact factor: 6.551

6.  Epigenome-wide DNA methylation profiling of portal vein tumor thrombosis (PVTT) tissues in hepatocellular carcinoma patients.

Authors:  Xiaoxiao Fan; Yirun Li; Xin Yi; Guoqiao Chen; Shengxi Jin; Yili Dai; Bin Cui; Binghua Dai; Hui Lin; Daizhan Zhou
Journal:  Neoplasia       Date:  2020-10-13       Impact factor: 5.715

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.